NeuroOne Q2 product revenue surges to $466K; net loss $3.5M; Evo sEEG launched

NEUROONE MEDICAL TECHNOLOGIES Corp

2023-Q2 EPS reported -$0.32 revenue$580,755

Product revenue $466K in Q2 (vs $37K YoY); collaboration revenue $1.46M first half from Zimmer deal.
Net loss $3.5M for Q2 vs $3.1M prior year; operating expenses rose to $3.5M.
Cash and equivalents $4.6M as of Mar 31, down from $11.1M at Sep 30; no debt.
Commercial launch of Evo sEEG electrode with Zimmer Biomet; first cases at Mayo and Cleveland Clinic.
On track to submit 510(k) for OneRF ablation system in Q2 calendar 2023; new VP of Operations appointed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NEUROONE MEDICAL TECHNOLOGIES Corp reported fiscal second quarter 2023 ended March 31, 2023 results: revenue product revenue was $466,000, net income Net loss was $3.5 million for the fiscal second quarter 2023.

Period: fiscal second quarter 2023 ended March 31, 2023
Revenue: product revenue was $466,000
Net income: Net loss was $3.5 million for the fiscal second quarter 2023
Result: reported results

Exact text from the filing

Product revenue was $466,000 in the fiscal second quarter 2023, compared to product revenue of $37,000 in the fiscal second quarter 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

NEUROONE MEDICAL TECHNOLOGIES Corp filing history →

Source: SEC EDGAR

accession 0001213900-23-038538

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.